November 12th 2024
Camizestrant showed better progression-free survival than fulvestrant across various subgroups of patients with advanced breast cancer.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
ER-Positive, Negative Breast Cancers Have Different Long-Term Recurrence Risks
January 21st 2016Breast cancer survivors with estrogen receptor (ER)-positive disease had a lower annual risk of recurrence within the first 5 years after diagnosis, though these patients then had higher rates than ER-negative patients after 5 years.
Incomplete Estrogen Suppression Seen in Breast Cancer Patients Assigned Exemestane, Triptorelin
January 6th 2016A substudy of the SOFT trial found that a number of patients assigned to adjuvant treatment with the aromatase inhibitor exemestane plus triptorelin do not achieve complete reductions in their estrogen levels.
Buparlisib Benefits Women With PIK3CA Mutations in Circulating Tumor DNA
December 11th 2015Women with advanced endocrine-resistant breast cancer who had PIK3CA mutations in their circulating tumor DNA had an almost 4-month progression-free survival improvement when adding the PIK3CA inhibitor buparlisib to fulvestrant.
Capecitabine Further Improved Outcomes of Residual Breast Cancer After Neoadjuvant Therapy
December 9th 2015Patients with breast cancer who still had residual disease after undergoing neoadjuvant chemotherapy and surgery had improved survival outcomes with the addition of adjuvant capecitabine to standard treatment.
Dual HER2 Blockade Fails to Improve Response Rate in HER2-Positive Breast Cancer
November 19th 2015Dual HER2 blockade with trastuzumab and lapatinib was no better than trastuzumab alone in producing pathologic complete responses in metastatic HER2-positive breast cancer patients in the neoadjuvant setting, according to a new study.